Transgene Biotek Ltd Management Discussions

CAUTION

Statements in the Management Discussion and Analysis describing the Company s and its subsidiaries objectives, projections, estimates and expectations may be forward-looking statements within the meaning of applicable laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the Company s operations include among others, climatic conditions, economic conditions affecting demand-supply and price conditions in the domestic and overseas markets in which the Company operates, changes in the Government regulations, tax laws and other statutes and other incidental factors.

(a) Alternative drug delivery technologies and opportunities

For many decades treatment of an acute diseases or illness has been mostly accomplished by delivery of drugs to the patients by various conventional delivery systems. The drug delivery method is chosen based upon the physiological properties of drug, the desired site of action, the biological barrier including drug metabolism that must be overcome to deliver the drug. The most common conventional method to delivery is oral, parenteral, transdermal, ophthalmic, nasal, rectal and anal. Three areas of potential challenges accounts in the exploration of alternate controlled release drug administration which are development of system which can be capable of delivering the drug at a therapeutically effective rate to a desired site for duration required for optimal treatment, modulation of gastrointestinal transit time and minimization of hepatic first pass elimination.

Alternate drug delivery systems are continuously being developed as many of the new drugs have low solubility and degradation against enzymatic acid catalyzed breakdown in the human body. Alternate drug delivery systems are the means of enhancing the therapeutic benefit of drug controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity immunogenicity and efficacy. Based on their technical sophistication Alternate drug delivery system can be classified as Rate preprogrammed, Activation modulated, Feedback regulated, Carrier based drug delivery system. There are many future challenges to be met like, technologies for self-assembly, virus-like systems for intracellular delivery, carriers for tissue engineering, cell and gene targeting systems, better disease markers in terms of sensitivity and specificity.

Unfortunately, though Transgene set off on a highly promising note on oral delivery of Insulin, enormous number of challenges from the regulatory point of view during the course of last 13-14 years impacting the progress of technology to its conclusion.

Internal Auditing and Controls

The internal control systems of the Company are adequate and commensurate with the size of operations. These controls ensure that transactions are authorized, recorded and reported on time. They ensure that assets are safe guarded and protected against loss or unauthorized disposal.

The Internal Audit department carried out audits in different areas of the Company s operations. Post-audit reviews were carried out to ensure that audit recommendations were implemented.

The Audit Committee of the Board of Directors reviewed the audit program and findings of the Internal Audit department.

Outlook

The outlook for Transgene, in view of several challenges on various fronts with limitations and restrictions imposed by SEBI is challenging till the ordersare vacated by SAT, Mumbai and Appellate Tribunal, Delhi. Till that period, the path forward will be to look for a strategic alternative.

CORPORATE GOVERNANCE REPORT

1. COMPANY S PHILOSOPHY ON CORPORATE GOVERNANCE

Transgene s governance framework is driven by the objective of enhancing long term stakeholder value without compromising on ethical standards and corporate social responsibilities. Efficient corporate governance requires a clear understanding of the respective roles of the Board of Directors

( " Board " ) and of senior management and their relationships with others in the Corporate Governance

Report.

Corporate governance philosophy of Transgene represents core values by which policies and practices of the organization are guided.

Corporate governance at Transgene is implemented through robust governance processes, internal control systems and processes, and strong audit mechanisms.

In this report, we have provided details on how the corporate governance principles are put in to practice at Transgene.

The corporate governance philosophy at Transgene stems from the set of principles and framework embedded in its values since the year 1992 adhering to the best practices possible. Our ethical framework focuses on long-term shareholder value creation through responsible decision making. Transgene s corporate governance framework is founded on the following pillars:

Accountability

For us, accountability is about holding ourselves firmly responsible for what we believe in and for delivering what we have promised. We ensure this by promoting a mind-set of ownership throughout the organization. By means of openness and transparency, we consider ourselves accountable to our stakeholders, our employees, shareholders, vendors and, government agencies.

Competent leadership and management

We believe in a dynamic and diverse board and we endeavor to maintain a board composition that brings healthy balance of skills, knowledge and, independence.

Sustainability

At Transgene, sustainability is about effectively managing the day to day and longterm challenges covering the financial, social and technical aspects, whilst focusing on business continuity. We are committed to pursuing our vision and reaching the set goals.

Compliance and risk management

We firmly believe in full adherence to all regulatory and statutory requirements in letter and spirit. Our operating environment is characterized by several risks, which can potentially impact our current and future goals. We believe that effective compliance and risk management activities will drive the sustainability of corporate performance. Our philosophy is imbibed on strict adherence to the governance mechanism laid down in the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( " Listing Regulations " ).

2. BOARD OF DIRECTORS & GOVERNANCE STRUCTURE

The Board of Directors (the Board) is responsible for strategic supervision, overseeing the management performance and governance of the Company on behalf of the shareholders and other stakeholders. The Board exercises independent judgement and plays a vital role in the oversight of the Company s affairs. The Board also ensures adherence to the standards of Corporate Governance and transparency in the Company s functioning.

The responsibility for identifying and evaluating a suitable candidate for the Board is delegated to the Nomination and Remuneration Committee (NRC). While selecting a candidate, the NRC reviews and evaluates the Board s composition and diversity to ensure that the Board and its committees have the appropriate mix of skills, experience, independence and knowledge for continued effectiveness.

The information on composition and category of directors as well as attendance of each director at the meetings of the Board of Directors held during the year ended on March 31, 2025, and at the last annual general meeting and their directorships in other companies and committee membership in other public companies as of the year-end is as under:

Name of Category No. of board Attendance No. of other Director meetings at the last Directorships attended AGM

Dr. K. Koteswara Chairman & MD 4 Yes Two Rao Promoter Mrs. SujanaKadiam Non-executive 4 Yes None Independent Mrs. Swetha Marri Non-executive 4 Yes None Independent Mr. Santosh Kumar Non-executive 4 Yes None Independent

3. MEETINGS & REVIEW:

The Board of Directors is the apex body constituted by shareholders and is vested with the powers of governance, control, direction and management of affairs of the Company. The Board provides strategic direction and guidance to the Companyand has been steering the Company towards achieving its objectives. Driven by the principles of corporate governance philosophy, the Board strives hard to work in best interest of the Company and its stakeholders.

The Board of Directors of the company met 4 (Four) times during the last financial year ended on 31 st March 2025. These meetings were held on 30 th May 2024, 10 th August 2024, 12 th November 2024 and 24 th January 2025. The company placed before the Board: ?€  quarterly and annual consolidated and standalone results & financial statements of the Company; ?€  Minutes of meetings of the Board and Board Committees, resolutions passed by circulation, and information pertaining to the subsidiary company; ?€  Any material default in financial obligations to and by the Company or substantial non-payment for services provided by the Company;

?€  Quarterly compliance certificates include noncompliance, if any, of regulatory, statutory nature or listing requirements and shareholders service;

?€  Appointment, remuneration and resignation of Directors; ?€  Formation/re-constitution of Committees; ?‚? Disclosures received from Directors;

?‚? Proposals requiring strategic guidance and approval of the Board; ?‚? Related party transactions; ?‚? Regular business / function updates; ?‚? Significant changes in accounting policies and internal controls; ?‚? Report on action taken on previous Board meeting decisions; ?‚? Reviewing and guiding the corporate strategy and. ?‚? risk assessment and minimization procedures.

The Company places all information, as and when applicable, as specified in Part A of Schedule II of the Listing Regulations before the Board of Directors.

4. CODE OF CONDUCT

The Board has laid down the code of conduct for members of the Board and senior management personnel of the Company. Board members and senior management personnel has affirmed compliance with the code and based thereon a declaration by managing director of the Company in this regard has been annexed to this report.

5. RELATIONSHIPS BETWEEN DIRECTORS INTER-SE

There is no relationship between any of the Directors and none of the non-executive directors hold any shares of the Company as on March 31, 2025.

6. AUDIT COMMITTEE

The composition of the Audit Committee complies with the requirement laid down in the Listing Regulations as well as Companies Act, 2013. Mrs. SujanaKadiam is Chairman of the Audit Committee, while Ms. Swetha Marri and Dr K. Koteswara Rao are the other members of the Audit Committee. The Audit Committee reviews information specified in Section B of Part C of Schedule II of the Listing Regulations, to the extent applicable.

The terms of reference of the Audit Committee are as per the provisions of Section 177 of the Companies Act, 2013 and the Listing Regulations. The terms of reference are:

?‚? Oversight of the Company s financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;

?‚? Recommendation for appointment, remuneration and terms of appointment of auditors of the Company;

?‚? Approval of payment to statutory auditors for any other services rendered by the statutory auditors;

?‚? Reviewing, with the management, the annual financial statements and auditors report thereon before submission to the Board for approval;

?‚? Reviewing, with the management, the quarterly financial statements before submission to the Board for approval; ?‚? Monitoring the end use of funds raised through public offers and related matters;

?‚? Review and monitor the auditors independence and performance, and effectiveness of audit process; ?‚? Valuation of undertakings or assets of the Company, wherever it is necessary; ?‚? Evaluation of internal financial controls and risk management systems; ?‚? Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;

?‚? Discussion with internal auditors of any significant findings and follow up thereon;

?‚? Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;

?‚? Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;

?‚? Approval or any subsequent modifications of transactions of the Company with related parties as per the Companies Act, 2013 and Listing Regulations;

?‚? Examination of the financial statements and the auditors report thereon; and

?‚? Such other items of business as the Companies Act, 2013, rules made there under and the Listing Agreement for the time being in force requires or may hereinafter require the audit committee to consider, review, evaluate, examine, scrutinize, value, approve, monitor, report, note or otherwise.

The Board of Directors of the company met 4 (Four) times during the last financial year ended on 31 st March 2025. These meetings were held on 30 th May 2024, 10 th August 2024, 12 th November 2024 and 24 th January 2025. The company placed before the Board:

The attendance of each member of the Committee is given below:

NAME OF THE DIRECTOR	NO. OF MEETINGS
	ATTENDED
Mrs. SujanaKadiam	4
Mrs. Swetha Marri	4
Dr. K. Koteswara Rao	4
Mr. Santosh Kumar	4

7. SHARE TRANSFER COMMITTEE

The Stakeholders Relationship Committee comprising Dr K Koteswara Rao and Mrs. SujanaKadiam, have been assigned the work of redressal of investors/ Shareholders complaints along with approval of share transfer, sub-division/ consolidation of shares, etc. The Committee oversees the performance of Registrar and Share Transfer Agents and recommends measures for overall improvement of the quality of investor services. The Share Transfers / Transmissions approved by the committee are placed at the Board Meeting from time to time. The complaints received from the investors are being regularly attended to and are believed to be resolved to their satisfaction. The status of the investors complaints is reviewed by the Stakeholders Relationship Committee generally on quarterly basis.

During the year, the Company received 1 investor complaint which has been attended to and believed to have been resolved to the satisfaction of the investors. Thus, no investor grievance was pending at the year-end.

COMPLIANCE OFFICER

There are no changes in Compliance officer during the year.

8. REMUNERATION OF DIRECTORS

The details of remuneration paid to Directors are given below:

NAME OF THE DIRECTOR	RELATIONSHIP WITH OTHER DIRECTORS	SITTING FEE (Rs.)	SALARY & PERKS (Rs.)	TOTAL (Rs.)
Dr. K. Koteswara Rao	None	0/-	0	0
Ms. Swetha Marri	None	20,000/-	0	20,000/-
Ms. SujanaKadiam	None	20,000/-	0	20,000/-
Mr.Santosh Kumar	None	20,000/-	0	20,000/-
Total		60,000/-	0	60,000/-

9. DISCLOSURES

?‚? The Company has not entered any materially significant related party transaction with any related party that may have potential conflict with the interest of the Company at large.

?‚? In view of the several impending issues, the management raised an amount of Rs.6 Crs as a secured debt, subsequent to the receipt of shareholder approval at the AGM on 5 th December 2024.

SBIRI/BIRAC: The Department of Biotechnology had sanctioned a loan amount of Rs.4.07 Crores on 26 th March 2010 under Small Business Innovative Research Initiative (SBIRI) scheme currently called as BIRAC for the novel technology upgradation for Orlistat production, for which a charge against movable and immovable assets acquired and for utilization of the said loan amount has been created. The company has earlier repaid 20 L towards the principal amount. However, BIRAC has demanded a total amount of Rs. 7.58 Cr towards the outstanding Principal amount of Rs.3.87 Cr along with penal interest. The company since then has paid an amount of Rs.3.87 Crs on 1 st February 2025 with a request to accept it as a full and final settlement. We have not yet received the confirmation of acceptance from BIRAC on that request. ?‚? The Company has complied with all requirements of corporate governance report of sub-paras (2) and (10) of the Part C of Schedule V of the Listing Regulations. The Company has also submitted to the Exchanges periodical compliance reports on corporate governance within the prescribed period. ?‚? During the year, there were no transactions of material nature with the Directors or the Management or the subsidiaries or relatives that had potential conflict with the interests of the company.

10. MEANS OF COMMUNICATION

The company publishes its quarterly results in the Regional vernacular News Paper and National Newspaper.

The company has a website www.transgenebiotek.com where all the official news releases and the developments that are taking place in relation to the company are updated and displayed. There is also an email address for receipt of any complaints: info@transgenebiotek.com .

11. AUDITORS CERTIFICATE ON COMPLIANCE OF CONDITIONS OF CORPORATE

GOVERNANCE

A Certificate from the Auditors is enclosed along with this report.

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 09 of the Companies (Appointment and Remuneration Personnel) Rules, 2014] To The Members, M/s. Transgene Biotek Limited CIN: L85195TG1990PLC011065

I, Geeta Serwani, Proprietor of M/s. Geeta Serwani and Associates, Practicing Company Secretary have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Transgene Biotek Limited ( CIN: L85195TG1990PLC011065 )(hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company s books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit, I hereby report that in my opinion , the Company has during the audit period covering the financial year ended on March 31, 2025 complied with the Statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2025, according to the provisions of:

1. The Companies Act, 2013 (the Act) and the rules made there under;

2. The Securities Contracts (Regulation) Act, 1956(SCRA) and the rules made there under;

3. The Depositories Act, 1996 and the Regulations and Bye-law framed hereunder;

4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment and Overseas Direct Investment;

5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India, 1992 ( SEBI Act );The Securities and Exchange Board of India(Substantial Acquisition of

Shares and Takeovers) Regulations, 2011;

(a) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992; (b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 - Not Applicable (c) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 - Not Applicable (d) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 - Applicable (e) The Securities and Exchange Board of India (Registration to an Issue and Share Transfers Agents) Regulations, 1993; (f) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;

Not Applicable

(g) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 - Not Applicable I have also examined compliance with the applicable clause of the following: I. The Secretarial Standards issue by the Institute of Company Secretaries of India .

II. The Listing Agreements entered into by the Company with BSE Limited and Securities and

Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Accordingly, the Industry specific major Acts as applicable to the Company are complied.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc mentioned above.

I further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting.

All decision at Board Meetings and Committee Meetings are carried unanimously as recorded in the minutes of the Meetings of the Board of Directors or Committee of the Board, as the case may be.

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that -

1. As per SEBI (LODR) Regulations, 2015 Regulation No. 13, 22 and 23, policies for Grievance Redressal Mechanism, Vigil mechanism and Related party transactions are not framed.

2. As per SEBI (LODR) Regulations, 2015 Regulation 46, circulars and other regulations, theinformation s are not available /updated on the website of the company.

3 . The Company is required to maintain a Structured Digital Database (SDD) and comply with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, including maintenance of an audit trail and submission of SDD compliance reports to the Stock Exchange, wherever applicable. During the year under audit, the Company has not maintained a Structured Digital Database (SDD) and has not filed the requisite SDD compliance reports with the Stock Exchange. In our opinion, this constitutes a non-compliance with the aforesaid SEBI regulations.

4. Brief on SEBI and GDR issue :

Securities and Exchange Board of India (SEBI) initiated a preliminary inquiry upon receiving complaints regarding the Global Depository Receipts (GDRs) issued by the Company and the manner in which the GDR proceeds were utilized. SEBI, on a prima facie basis, observed that the GDR proceeds had been transferred by the Company, directly or indirectly, through its foreign subsidiary for undisclosed purposes under the guise of consideration for technology transfer . SEBI considered this as a potential violation affecting investor protection and, accordingly, passed an interim order restraining the Company from issuing any securities. The Company has appealed against the said order. The observations in SEBI s interim findings also indicated potential violations of the Foreign Exchange Management Act (FEMA) and the terms of the original GDR approval.

SEBI, vide its final order dated August 28, 2019 (Ref: WTM/AB/EFD-1/DRA-4/18/2019-20) , confirmed its earlier directions and continued the restraint on the Company from accessing the securities market in any manner . Further, SEBI directed the Company to recover the GDR proceeds through its available measures within one year from the date of the order.

Subsequently, a representation was made by Dr. K. Koteswara Rao on August 22, 2020 seeking an extension of time to bring back the funds, pointing out that recovery efforts had been severely impacted due to the global COVID-19 pandemic. SEBI considered the representation and issued a revised order dated August 31, 2020 (Order No. WTM/AB/EFD-1/DRA-4/08/2020-21) , granting a fresh period of one year from that date to recover the GDR proceeds.

Further, SEBI, through its Adjudication Order dated June 27, 2022 , imposed a penalty of 38 lakhs on the Company and monetary penalties on certain erstwhile Directors associated with the GDR issue period. The Company has informed that it has challenged this order before the Securities Appellate Tribunal (SAT) vide Appeal No. 769/2022 , along with Miscellaneous Application No. 1173/2022 , and therefore has not paid the penalty. Following non-payment, SEBI has frozen the

Company s bank and demat accounts pending directions from SAT.

Additionally, a Common Affidavit-in-Rejoinder dated September 23, 2024 has been filed in Appeal No. 812/2022 , on behalf of (i) Transgene Biotek Ltd., (ii) Dr. K. Koteswara Rao (Appeal 813/2022), and (iii) Narayana Murthy Pentyala (Appeal 814/2022). The appellants have submitted that the balance of convenience lies in their favor and have requested that the impugned order be set aside. They have further sought appropriate directions to SEBI to conduct a thorough investigation in line with the findings of the Enforcement Directorate, and to facilitate repatriation of USD 39.34 million , allegedly siphoned from the Company s foreign bank accounts by Mr.

Nirmal Kotecha and associates, which the Company asserts is the property of the Company and its investors.

5. Despite paying off the charges created with bankers and financial institution various charge ID s are still showing active on MCA 21 website in Index of Charges. Charge ID 10116760, 90343651, 90343130, 90342903, 90338686, 90342767 as per Audited Balance sheet as on 31.03.2025 and representation made by management there are no dues pending for these active charges showing on MCA 21 website. Reasons of non-filling of CHG 4 forms with MCA 21 for satisfaction of charges are various such as merging of Banks, shifting of bank branches etc.

6. Independent Directors Databank Registration

Ms. Sujana Kadiam, and Mr. Santhosh Kumar, Independent Directors of the Company, have not renewed their registration in the Independent Directors Databank maintained by the Indian

Institute of Corporate Affairs (IICA), as required under Section 150 of the Companies Act, 2013 read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014.

7. Expiry of Independent Directors Term Without Reappointment The first term of Independent Directors Ms. Swetha Marri, Ms. Sujana Kaidam, and Mr. Santhosh Kumar has expired, and they have not been reappointed for a second term in the General Meeting, as required under Regulation 25(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This constitutes a non-compliance with the said Regulation.

8. Enforcement Directorate Adjudication Order.

The Company has received an Adjudication Order from the Enforcement Directorate, Southern Regional Office, Chennai, dated 30 December 2024, imposing a monetary penalty of 203.02 crores for alleged contraventions under the Foreign Exchange Management Act, 2000, in connection with the GDR issue.

The Company has filed an appeal before the Appellate Tribunal, New Delhi, challenging the said order. The matter was listed for hearing on 25 March 2025 and has been getting adjourned with the next date for hearing adjourned to 5 th January 2026.

We further report that during the audit period, there were no specific events / actions having a major bearing on the company s affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc., referred to the above.

Geeta Serwani& Associates (Practicing Company Secretary)

Sd/-

(Geeta Serwani) Proprietor FCS: 8991, COP: 8842 Place: Hyderabad

Date: 14.11.2025UDIN F008991G001898736

Note: This report is to be read with letter of even date which is annexed as " ANNEXURE A " and forms an integral part if this report.

Annexure A

To

The Members

Transgene Biotek Limited

The Report of even date is to be read along with this letter.

1.) Maintenance of Secretarial Records is the responsibility of the management of the Company. My responsibility is to express an opinion on these Secretarial records based on my audit. My examination was limited to verification of procedure on testbasis.

2.) I have followed the Audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are recorded in Secretarial records. I believe that the process and practices, I followed provide a reasonable basis for my opinion.

3.) I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4.) Wherever required I have obtained the management representation about the Compliance of Law, rules and Regulations and happening of events etc.

5.) The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Geeta Serwani& Associates (Practicing Company Secretary)

Sd/-

(Geeta Serwani)
Proprietor
FCS: 8991, COP: 8842
Place : Hyderabad
Date : 14.11.2025	UDIN F008991G001898736